胰岛素抵抗对老年非心脏手术患者认知功能的影响及相关性研究

注册号:

Registration number:

ChiCTR1800019768 

最近更新日期:

Date of Last Refreshed on:

2018-11-27 23:44:04 

注册时间:

Date of Registration:

2018-11-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

胰岛素抵抗对老年非心脏手术患者认知功能的影响及相关性研究

Public title:

Correlation and effects of insulin resistance on cognitive function in elderly patients with non-cardiac surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胰岛素抵抗对老年非心脏手术患者认知功能的影响及相关性研究

Scientific title:

Correlation and effects of insulin resistance on cognitive function in elderly patients with non-cardiac surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

贺喜 

研究负责人:

欧阳文 

Applicant:

Xi He 

Study leader:

Wen Ouyang 

申请注册联系人电话:

Applicant telephone:

+86 15111283669

研究负责人电话:

Study leader's
telephone:

+86 13974934441

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

53248183@qq.com

研究负责人电子邮件:

Study leader's E-mail:

ouyangwen133@vip.sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市河西岳麓区桐梓坡路138号 麻醉科

研究负责人通讯地址:

湖南省长沙市岳麓区桐梓坡路138号湘雅三医院

Applicant address:

138 Tongzipo Road, Yuelu, Changsha, Hu'nan, China

Study leader's address:

138 Tongzipo Road, Yuelu, Changsha, Hu'nan, China

申请注册联系人邮政编码:

Applicant postcode:

410000

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中南大学湘雅三医院麻醉科

Applicant's institution:

Anesthesiology department, The Third Xiangya hospital of Central South University

研究负责人所在单位:

中南大学湘雅三医院麻醉科

Affiliation of the Leader:

138 Tongzipo Road, Yuelu, Changsha, Hu'nan, China

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

快18178

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中南大学湘雅三医院伦理委员会医学伦理分委员会

Name of the ethic committee:

Medical ethics subcommittee of ethics committee of xiangya third hospital, central south university

伦理委员会批准日期:

Date of approved by ethic committee:

2018-11-23 00:00:00

伦理委员会联系人:

粟志英

Contact Name of the ethic committee:

Zhi ying Su

伦理委员会联系地址:

湖南省长沙市岳麓区桐梓坡路138号湘雅三医院伦理科

Contact Address of the ethic committee:

Ethical department,138 Tongzipo Road, Yuelu, Changsha, Hu'nan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 0731-88618938

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中南大学湘雅三医院

Primary sponsor:

The Third Xiangya hospital of Central South University

研究实施负责(组长)单位地址:

湖南省长沙市岳麓区桐梓坡路138号湘雅三医院

Primary sponsor's address:

138 Tongzipo Road, Changsha, Hu'nan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

长沙

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

中南大学湘雅三医院

具体地址:

湖南省长沙市河西岳麓区桐梓坡路138号

Institution
hospital:

The Third Xiangya hospital of Central South University

Address:

138 Tongzipo Road, Yuelu, Changsha, China

经费或物资来源:

高校科研经费

Source(s) of funding:

Scientific research funds of colleges and universities

研究疾病:

术后谵妄和术后认知功能障碍  

Target disease:

Postoperative Delirium and Postoperative Cognitive Dysfunction

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

胰岛素抵抗程度与术后POD 及POCD的发生率,研究老年患者代谢,胰岛素抵抗以及POD和POCD发病机制  

Objectives of Study:

The degree of insulin resistance and the incidence of POD and POCD ; Investigate the metabolism, insulin resistance and the pathogenesis of POD and POCD in elderly patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 患者或/和家属拒绝参加研究;
2. 既往中枢神经系统疾病(如痴呆、肌萎缩脊髓侧索硬化症、精神病、严重脑血管病、癫痫、Parkinson’s病、颅内肿瘤)
3. 药物滥用史(如服用过镇静药和/或抗抑郁药);
4. 有视觉、听觉障碍或不能配合行认知功能评估的患者;
5.主治医生或研究者认为存在其他不宜参加本研究的情况【需记录原因】。

Exclusion criteria:

1. patient or family member's refusal and attitude unknown;
2. There is a central nervous system disease (such as AD,amyotrophic lateral sclerosis, mental disease,epilepsy,Parkinsons,intracranial tumours);
3. Drug abuse(such as sedative and/or antidepressant;
4. Severe hearing or visual impairment, end-stage disease can not communicate;
5. The attending physician or researcher believes there are other conditions that should not be included in this study(need record).

研究实施时间:

Study execute time:

From 2018-11-28 00:00:00 To 2020-05-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-11-28 00:00:00 To 2020-05-29 00:00:00

干预措施:

Interventions:

组别:

手术组

样本量:

300

Group:

Operation group

Sample size:

干预措施:

干预措施代码:

Intervention:

NO

Intervention code:

组别:

非手术组

样本量:

30

Group:

No operation group

Sample size:

干预措施:

干预措施代码:

Intervention:

NO

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

Hu'nan

City:

Changsha

单位(医院):

中南大学湘雅三医院 

单位级别:

三甲医院 

Institution
hospital:

The Third Xiangya hospital of Central South University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

术后认知功能障碍

指标类型:

主要指标

Outcome:

Postoperative cognitive dysfunction

Type:

Primary indicator

测量时间点:

测量方法:

神经心理学测试

Measure time point of outcome:

Measure method:

Neuropsychological test

指标中文名:

术后谵妄

指标类型:

主要指标

Outcome:

Postoperative delirium

Type:

Primary indicator

测量时间点:

测量方法:

CAM-ICU

Measure time point of outcome:

Measure method:

CAM-ICU

指标中文名:

胰岛素抵抗相关指标

指标类型:

主要指标

Outcome:

insuline resistance related indicators

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

代谢及炎症相关指标

指标类型:

主要指标

Outcome:

metabolism and inflammation related indicators

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

劲动脉血管彩超

指标类型:

主要指标

Outcome:

Carotid artery blood vessels

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 95 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本试验为前瞻性观察性研究,无随机方法

Randomization Procedure (please state who generates the random number sequence and by what method):

This study was a prospective observational study with no randomized method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在中国临床试验注册中心共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

sharing in Chinese clinical trial registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2018-11-27 23:42:53